

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Oncologica

Supplementary material:

Table S1: Survival in follow-up

Survival in follow-up	n (%)
All-cause mortality	203 (82.2)
Progression of disease lung cancer	119 (48.2)
Infection or sepsis	38 (15.4)
Sudden cardiac death	6 (2.4)
Other cardiac condition; AFLI, AMI etc.	10 (4)
Radiation pneumonitis	5 (2)
Other pulmonary condition; COPD, etc.	12 (4.9)
Other or unknown	21 (8.5)
Median overall survival [median months post-RT (95% CI)]	27.4 (24.5 - 35.7)
Median survival with DNAF [median months post-RT (95% CI)]	3.9 (2.3 - 10.9)
Median survival with DNHD [median months post-RT (95% CI)]	4.9 (3.9 - 14.4)
Survival in follow-up	n (%)
All-cause mortality	203 (82.2)
Progression of disease lung cancer	119 (48.2)
Infection or sepsis	38 (15.4)
Sudden cardiac death	6 (2.4)
Other cardiac condition; AFLI, AMI etc.	10 (4)
Radiation pneumonitis	5 (2)
Other pulmonary condition; COPD, etc.	12 (4.9)
Other or unknown	21 (8.5)
Median overall survival [median months post-RT (95% CI)]	27.4 (24.5 - 35.7)
Median survival with DNAF [median months post-RT (95% CI)]	3.9 (2.3 - 10.9)
Median survival with DNHD [median months post-RT (95% CI)]	4.9 (3.9 - 14.4)